Lineage Cell Therapeutics (LCTX) Receivables (2011 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Receivables of $1.4 million for Q1 2026, up 553.05% year-over-year from $213000.0 in Q1 2025, and down 10.95% quarter-over-quarter from $1.6 million in Q4 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Receivables (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Receivables history runs 16 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Receivables rose 553.05% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (up 553.05% YoY), while the FY2025 annual figure was $1.6 million, up 144.83% from the prior year.
- Receivables for Q1 2026 stood at $1.4 million, down from $1.6 million in the prior quarter.
- The five-year high for Receivables was $1.6 million in Q4 2025, with the low at $77000.0 in Q1 2024.
- The 5-year median for Receivables is $432000.0 (2023), against an average of $583823.5.
- The sharpest annual moves came in 2022 and 2026: Receivables plunged 98.28% in 2022, then soared 553.05% in 2026.
- Lineage Cell Therapeutics' Receivables stood at $881000.0 in 2022, then declined by 15.44% to $745000.0 in 2023, then retreated by 14.36% to $638000.0 in 2024, then jumped by 144.83% to $1.6 million in 2025, then declined by 10.95% to $1.4 million in 2026.
- Business Quant data shows LCTX's Receivables at $1.4 million in Q1 2026, $1.6 million in Q4 2025, and $676000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | 956,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 956,000.00 |
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 676,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Mar 31, 2025 | 213,000.00 |
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Dec 31, 2023 | 745,000.00 |
| Sep 30, 2023 | 432,000.00 |
| Jun 30, 2023 | 443,000.00 |
| Mar 31, 2023 | 173,000.00 |
| Dec 31, 2022 | 881,000.00 |
| Sep 30, 2022 | 980,000.00 |
| Jun 30, 2022 | 732,000.00 |
| Mar 31, 2022 | 323,000.00 |
| Dec 31, 2021 | 51.18 Mn |
| Sep 30, 2021 | 2.12 Mn |